Sarcoidosis

Dr Robin H Johns
Consultant Respiratory Physician
Queens Hospital Romford 2019

Aetiology

- Sarcoidosis is a multi-system granulomatous disease of unknown cause
- Due to a dysregulated immune response involving antigen, HLA type II molecules, and T-cell receptors in patients with a susceptible genetic background
- May be triggered by more than one infectious agents/ exposures

Aetiology

Potential triggering factors:

- Infectious agents: Mycobacteria, Propionibacteria, Herpes viruses
- Environmental exposures (sarcoid more common in Firefighters in NYC post 9/11)
- Genes encoding HLA (MHC II), ACE, vit D receptor, IL-1, TNF-alpha, TCR

Saidha S et al, Yale J Biol Med 2012; 85(1); 133-141
Iannuzzi M et al, Proc Am Thorac Soc 2007; 4(1); 108-116

Aetiology

- Antigen exposure initiates exaggerated Th1 immune response
- Granulomas form around persisting antigen
- Condition resolves if antigen is cleared
- Switch from Th1 to Th2 response is associated with fibrosis



Source: Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ, Wolff K: *Fitzpatrick's Dermatology in General Medicine, 8th Edition*: www.accessmedicine.com

Copyright © The McGraw-Hill Companies, Inc. All rights reserved.

Epidemiology

- North Europeans and African Americans most affected
- Asians, Hispanics less often affected
- In USA, Prevalence is:
  - 141 per 100 000 in African Americans
  - 50 per 100 000 in White people
- Incidence peaks in men age 30-50 and in women age 50-60
- Incidence in UK is 5 per 100 000 people per year

Spagnolo P et al, Lancet Respir Med 2018; 6; 389-402

Typical Presentation

- Up to 50% of patients have pulmonary symptoms at diagnosis
- 20% present with extrapulmonary manisfestations
- 30% may be asymptomatic and diagnosed due to incidental abnormal CXR/ CT scan

- Most common symptoms:
    - Dyspnoea, wheeze, cough, chest discomfort (substernal)
    - Often Reactive airways with cough exposed by irritants
    - May be fever, weight loss, malaise, arthralgia

Lofgren's syndrome

- Lofgren's triad
  - Arthralgia
  - Erythema Nodosum
  - Bi-hilar lymphadenopathy





Lofgren's syndrome

- Arthralgia
- Erythema Nodosum
- Bi-hilar lymphadenopathy

Treat with immobilisation, NSAIDs, ± short course of glucocorticoids

Heerfodt's syndrome

A rare presentation of acute sarcoid



Heerfodt's syndrome

A rare presentation of acute sarcoid



from New England Journal of Medicine

Heerfodt's syndrome

A rare presentation of acute sarcoid

Treat with glucocorticoids (as per neurosarcoid) given nerve palsy

Sarcoidosis is a Multi-System Disorder

But Sarcoidosis is evident in the lungs in 90-95% of patients at the time of diagnosis



Carey, W. D., & Cleveland Clinic Foundation. 2010. Current clinical medicine. Philadelphia: Saunders Elsevier

Anterior Uveitis



A Colour Atlas and Text of Clinical Medicine, Forbes and Jockson (Eds), Mosby-Wolfe (Pubs) 1993

Skin sarcoid







A Colour Atlas and Text of Clinical Medicine, Forbes and Jockson (Eds), Mosby-Wolfe (Pubs) 1993

Radiological features – CXR

Scadding scale

- Stage I: bilateral hilar adenopathy (40-50% of patients at presentation)
- Stage II: bilateral hilar adenopathy and upper zone reticular opacities (30-40% of patients)
- Stage III: shrinking bilateral hilar adenopathy with upper zone reticular opacities (15-20% of patients)
- Stage IV: upper zone reticular opacities with volume loss, conglomerated masses with marked traction bronchiectasis, calcification and cyst formation (2-5% of patients).



Baughman RP & du Bois (Eds), Diffuse Lung Disease 2012, Springer (pubs)

Radiological features – CT scan

- Hilar and mediastinal lymphadenopathy
- Beaded or irregular thickening of the bronchovascular bundles
- Nodules along bronchi, vessels, fissures, and subpleural regions
- Bronchial wall thickening
- Ground glass opacification
- Parenchymal masses or nodular consolidation, occasionally with cavitation
- Parenchymal bands
- Cysts
- Fibrosis with distortion of the lung architecture and traction bronchiectasis

Mediastinal Lymphadenopathy



By Hellerhoff - Own work, CC BY-SA 3.0,
https://commons.wikimedia.org/w/index.php?curid=7567689

Nodular infiltrates



Radiopaedia

Diffuse infiltrates



Endobronchial granulomatous disease at Bronchoscopy



A Colour Atlas and Text of Clinical Medicine, Forbes and Jockson (Eds), Mosby-Wolfe (Pubs) 1993

Bronchoalveolar Lavage

I. Normal Adults (Nonsmokers)	BAL Differential Cell Counts
Alveolar macrophages	>85%
Lymphocytes (CD4+/CD8+ = 0.9–2.5)	10–15%
Neutrophils	≤3%
Eosinophils	≤1%
Squamous epithelial*/ciliated columnar epithelial cells†	≤5%

a. Disorders associated with increased percentage of specific BAL cell types

Lymphocytic cellular pattern	Eosinophilic cellular pattern	Neutrophilic cellular pattern
>15% lymphocytes	>1% eosinophils	>3% neutrophils
Sarcoidosis	Eosinophilic pneumonias	Collagen vascular diseases
Nonspecific interstitial pneumonia (NSIP)	Drug-induced pneumonitis	Idiopathic pulmonary fibrosis
Hypersensitivity pneumonitis	Bone marrow transplant	Aspiration pneumonia
Drug-induced pneumonitis	Asthma, bronchitis	Infection: bacterial, fungal
Collagen vascular diseases	Churg-Strauss syndrome	Bronchitis
Radiation pneumonitis	Allergic bronchopulmonary aspergillosis	Asbestosis
Cryptogenic organizing pneumonia (COP)	Bacterial, fungal, helminthic, *Pneumocystis* infection	Acute respiratory distress syndrome (ARDS)
Lymphoproliferative disorders	Hodgkin's disease	Diffuse alveolar damage (DAD)

b. Abnormal BAL differential cell patterns that suggest specific types of ILD

A lymphocyte differential count ≥25% suggests granulomatous disease (sarcoidosis, hypersensitivity pneumonitis, or chronic beryllium disease), cellular nonspecific interstitial pneumonia, drug reaction, lymphoid interstitial pneumonia, cryptogenic organizing pneumonia, or lymphoma.
CD4+/CD8+ >4 is highly specific for sarcoidosis in the absence of an increased proportion of other inflammatory cell types.
A lymphocyte differential count >50% suggests hypersensitivity pneumonitis or cellular nonspecific interstitial pneumonia.
A neutrophil differential count >50% supports acute lung injury, aspiration pneumonia, or suppurative infection.
An eosinophil differential count >25% is virtually diagnostic of acute or chronic eosinophilic pneumonia.
A cell differential count of >1% mast cells, >50% lymphocytes, and >3% neutrophils is suggestive of acute hypersensitivity pneumonitis.

Uptodate 2017

EBUS Bronchoscopy & TBNA



Specimens obtained by endobronchial ultrasound–guided transbronchial needle aspiration in patients with sarcoidosis. A, Cytologic specimen showing non-necrotizing epithelioid cell granuloma. (Papanicolaou stain, original magnification ×200.) B, Histologic specimen containing noncaseating epithelioid cell granulomas (hematoxylin and eosin stain, original magnification ×100).

The Journal of Thoracic and Cardiovascular Surgery 2012 143, 1324-1329DOI: (10.1016/j.jtcvs.2012.01.040)

Copyright © 2012 The American Association for Thoracic Surgery Terms and Conditions

Diagnostic approach in sarcoidosis

- Diagnosis requires:

1. compatible clinical presentation
2. presence of noncaseating granuloma on histopathological examination
3. exclusion of other causes of granulomatous inflammation

- In Lofgrens or Heerfordt's syndrome diagnosis may be established on clinical grounds alone

Diagnosis in pulmonary sarcoidosis

Consider bronchoscopy and

i) Bronchoalveolar lavage (lymphocytic in sarcoid – also important to exclude infection/ TB)

ii) Endobronchial biopsy (70% diagnostic yield if cobblestone mucosa seen)

iii) Transbronchial lung biopsy if there are pulmonary infiltrates but no lymphadenopathy

iv) If there is isolated intrathoracic lymphadenopathy, EBUS TBNA (Endobronchial Ultrasound TransBronchial Needle Aspiration) has a higher diagnostic yield than tranbronchial lung biopsy (80% vs 15-66%)

Spagnolo P et al, Lancet Respir Med 2018; 6; 389-402

Differential Diagnosis of Mediastinal & Hilar Lymphadenopathy

- Sarcoidosis
- Infection (TB or Fungal)
- Lymphoma
- Metastatic cancer
- Berylliosis
- Histoplasmosis

Differential Diagnosis of Lymph Node Granulomatous Histology

- Sarcoidosis
- Tuberculosis
- Malignancy-induced granulomatous reaction (from Adenocarcinoma or Lymphoma)
- Berylliosis
- Histoplasmosis
- Brucellosis (cervical lymphadenopathy)
- Toxoplasmosis (cervical lymphadenopathy)
- Cat scratch disease (regional lymphadenitis)
- Common Variable Immunodeficiency Syndrome

Jeny F et al, Eur Respir Rev 2016; 25; 141-150
Baugman RP & du Bois (Eds), Diffuse Lung Disease 2012, Springer (pubs)

Diagnostic work up post biopsy in sarcoidosis

- Chest X-ray/ CT chest
- Spirometry & TLCO
- Liver function tests
- Complete blood count
- Opthalmological examination (slit lamp) – Eye clinic referral
- ECG (to exclude AV block and arrthymias)
- Serum calcium
- Urine calcium

Baughman RP & du Bois (Eds), Diffuse Lung Disease 2012, Springer (pubs)

Laboratory test patterns in sarcoidosis

- ↑ Serum Angiotensin Converting Enzyme (sensitivity 40%)
- Lymphopaenia
- Hypergammaglobulinaemia
- ↑ CRP/ ESR
- Abnormal LFT (24% of patients)
- ↑ serum calcium (5-10% of patients) (with normal PTH)
- ↑ urine calcium (>40% of patients)

Ahmadzai H et al, Current Biomarker Findings 2014; 4; 93-106

Hypercalcaemia in sarcoidosis



Iruzubieta P et al, World J Heptol 2014; 6(12); 901-915

Pulmonary Function Testing in sarcoidosis

- Often Obstructive spirometry with FEV1/VC <70% (present at diagnosis in 63% of patients)
- May be Restrictive with reduced TLCO more advanced fibrotic disease
- 6MWT and CPET are not usually indicated

- Serial FVC and TLCO are indicated to monitor disease
- Progressive disease shown by a fall in FVC by 10% and/or a fall in DLCO of 15% over a 3-6 month interval

Baughman RP & du Bois (Eds), Diffuse Lung Disease 2012, Springer (pubs)

PET scanning in sarcoidosis

Possible indications for PET scanning in sarcoidosis:

- To help to identify a site for biopsy
- Investigating/ monitoring cardiac sarcoidosis
- Searching for active pulmonary lesions in advanced fibrotic pulmonary sarcoidosis
- Searching for metabolic activity in patients with persisting disabling symptoms and normal biomarkers



Other imaging in sarcoidosis

- Gallium (Ga-67) scintigraphy may demonstrate the various sites of involvement by sarcoid:
  - May identify a biopsy site in suspected sarcoid
  - the “panda pattern” shows salivary gland uptake
  - the “lambda pattern” shows mediastinal and hilar node uptake
  - Both of these are considered specific for Sarcoidosis
  - Unfortunately whilst highly specific these findings are not sensitive (leading potentially to an underreporting of patients who may nonetheless have the disease).



A: Panda pattern; B lambda pattern

Allard AB et al, Modern Research in Inflammation 2014; 3; 99-107

Other imaging in sarcoidosis

- Gadolinium-enhanced MRI can detect sarcoid of brain, spinal cord, meninges, skull vault and pituitary lesions
- Echocardiography, Cardiac MRI, and Electrophysiological studies may be indicated in cardiac sarcoid

Indications for systemic treatment in sarcoidosis

- Severe Respiratory disease at presentation
- Progressive symptomatic pulmonary disease
- Persisting lung infiltrates and/or progressive loss of lung function
- Cardiac disease
- Neurological disease
- Eye disease not responding to topical therapy
- Symptomatic hypercalcaemia

Ahmadzai H et al, MJA 2018; 208(11); 499-504

Corticosteroids in sarcoidosis

PubMed.gov
US National Library of Medicine
National Institutes of Health

PubMed

Advanced

Format: Abstract

Send to

Thorax. 1996 Mar;51(3):238-47.

British Thoracic Society Sarcoidosis study: effects of long term corticosteroid treatment.

Gibson GJ[1], Prescott RJ, Muers MF, Middleton WG, Mitchell DN, Connolly CK, Harrison BD.

Author information

1 Sarcoidosis Subcommittee of the Research Committee of the British Thoracic Society.

Abstract

BACKGROUND: Corticosteroids suppress disease activity in pulmonary sarcoidosis and their use produces symptomatic, radiographic, and functional improvement. There is, however, uncertainty regarding their effects on the overall natural history of the condition and long term benefit is unproven.

METHODS: Patients with pulmonary radiographic shadowing due to sarcoidosis were recruited in a multicentre study. Those who, in the first six months after entry to the study, neither required prednisolone for symptoms nor showed radiographic improvement were allocated at six months to receive either long term steroid treatment (group L) or selective treatment (group S), with regular assessment over the subsequent five years. Patients in group L were scheduled to receive steroid treatment for at least 18 months with the policy of achieving and maintaining maximal radiographic clearing, while in group S treatment was reserved for use only if warranted by later development of symptoms or deteriorating lung function. Symptoms, radiographic appearances, and respiratory function were assessed periodically during the study.

RESULTS: One hundred and forty nine patients were followed: 33 required prednisolone for troublesome symptoms within six months of entry and 58 showed radiographic improvement over this period. The remaining 58 patients were allocated to groups L (n = 27) and S (n = 31). Patients in group L showed greater improvements in symptoms, respiratory function, and radiographic appearances than those in group S, although the differences were not large. After adjusting for differences at the time of allocation, the average difference in vital capacity between groups L and S at final assessment was 9% of the predicted value. Side effects of treatment were frequent but usually mild, necessitating withdrawal in only two individuals.

CONCLUSIONS: After excluding those individuals who required steroids for control of symptoms, approximately half of the remaining patients with sarcoidosis and pulmonary shadowing showed spontaneous radiographic improvement during six months of observation. In those in whom the radiograph failed to improve, prolonged steroid treatment with the aim of optimising radiographic appearances resulted in a significantly better long term functional outcome.

Prednisolone in sarcoidosis

- start Prednisolone 20-40mg/ day
- use Bishophosphonate and PPI but not Vit D/ Calcium
- begin to taper Prednisolone after 4 weeks to ≤ 10mg/day
- continue for at least 12 months (reduces likelihood of relapse)
- consider steroid-sparing strategy (e.g methotrexate) to reduce steroid-burden e.g. in poorly-controlled diabetes or obesity

Baughman RP & du Bois (Eds), Diffuse Lung Disease 2012, Springer (pubs)

Prednisolone in sarcoidosis

- If poor response increase prednisolone and add cytotoxic agent
- Taper prednisolone if response achieved
- If poor response to cytotoxic agent, trial 2nd cytotoxic agent or Biologic

Baughman RP & du Bois (Eds), Diffuse Lung Disease 2012, Springer (pubs)

Other treatments in sarcoidosis

- Inhaled corticosteroids may be useful for patients with cough/ asthmatic symptoms
- Hydroxychloroquine is beneficial for cutaneous sarcoid and hypercalcaemia
- Minocycline and Doxycycline may be useful for cutaneous sarcoid
- Protopic (topical tacrolimus) ointment is effective in cutaneous sarcoid
- Eyedrops containing corticosteroid ± cyclopegics (cyclopentolate or atropine) are used in ocular sarcoid

Baughman RP & du Bois (Eds), Diffuse Lung Disease 2012, Springer (pubs)

Cytotoxic therapy in sarcoidosis

In cases refractory to (or intolerant of) prednisolone

- **Methotrexate:** weekly dosing (10-25mg) with folic acid. Side effects nausea, fatigue, alopecia, rash, liver dysfunction, leukopenia, hypersensitivity pneumonitis, infection, increased cancer risk. Requires blood test monitoring of FBC, U&E, LFT
- **Azathioprine:** daily dosing (2-2.5mg/kg/day). Similar side effect profile to methotrexate but less hepatotoxic. Requires blood test monitoring of FBC, U&E, LFT
- **Leflunomide:** daily dosing (10-20mg/day).Similar side effect profile to methotrexate, including hepato- and pulmonary toxicity. Blood test monitoring required.
- **Mycophenolate:** daily dosing (2g/ day). Similar side effect profile. Less likely to be hepatottoxic than methotrexate, azathioprine, or leflunomide. Blood test monitoring required

Baughman RP & du Bois (Eds), Diffuse Lung Disease 2012, Springer (pubs)

Cytotoxic therapy in sarcoidosis

In cases refractory to (or intolerant of) prednisolone

- **Cyclophosphamide:** The most potent and toxic of the cytotoxics. Efficacy in refractory (CNS) sarcoid has been demonstrated. Requires very careful blood test monitoring. Side effects are common: neutropenia, infections, haemorrhagic cystitis, and malignancy.

Baughman RP & du Bois (Eds), Diffuse Lung Disease 2012, Springer (pubs)

Biologic therapy in sarcoidosis

PubMed.gov
US National Library of Medicine
National Institutes of Health

PubMed

Advanced

Format: Abstract

Send to

Semin Arthritis Rheum. 2019 Jun;48(6):1093-1104. doi: 10.1016/j.semarthrit.2018.10.005. Epub 2018 Oct 16.

Anti-tumor necrosis factor agents in sarcoidosis: A systematic review of efficacy and safety.

Adler BL[1], Wang CJ[2], Bui TL[3], Schilperoort HM[4], Armstrong AW[5].

Author information

1 Department of Dermatology, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States.
2 Keck School of Medicine, University of Southern California, Los Angeles, CA, United States.
3 University of California Irvine School of Medicine, Irvine, CA, United States.
4 Norris Medical Library, University of Southern California, Los Angeles, CA, United States.
5 Department of Dermatology, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States. Electronic address: armstrongpublication@gmail.com.

Abstract

BACKGROUND: Though anti-tumor necrosis factor agents (anti-TNFs) have been recommended as third-line therapy for sarcoidosis, an up-to-date systematic synthesis of their efficacy and safety is lacking.

OBJECTIVES: To systematically review the literature to characterize the efficacy and safety of anti-TNFs in sarcoidosis.

SETTINGS: All countries and treatment settings were included.

METHODS: We searched MEDLINE, EMBASE, CINAHL, Web of Science, ClinicalTrials.gov, Cochrane Library, and Google Scholar from inception to November 27, 2017. Studies of five or more cases of sarcoidosis treated with anti-TNFs were included. Descriptive statistics were performed.

RESULTS: Sixty-five studies (including five randomized controlled trials [RCTs]) were identified, comprising 1525 patients. For pulmonary sarcoidosis, one RCT found infliximab (IFX) significantly improved vital capacity vs. placebo; a second detected no difference. In non-randomized studies, IFX improved pulmonary function in 79% of patients. For cutaneous sarcoidosis, compared to placebo, adalimumab (ADA) showed greater Physician Global Assessment response and significantly reduced target lesion area, and IFX significantly decreased Sarcoidosis Area and Severity Index induration and erythema scores. In non-randomized studies of cutaneous, ocular, neurologic, and multisystem sarcoidosis, IFX improved 89%, 69%, 77%, and 71% of cases, respectively. ADA improved 77% of ocular sarcoidosis cases. IFX displayed a steroid-sparing effect. Half of patients relapsed after discontinuation of IFX, ADA, etanercept, or certolizumab pegol. In RCTs, compared to placebo, anti-TNFs had comparable overall and serious adverse events and slightly more serious infections.

CONCLUSIONS: Available evidence suggests the efficacy and safety of IFX in pulmonary, cutaneous, ocular, neurologic, and multisystem sarcoidosis, and ADA in cutaneous and ocular sarcoidosis.

Biologic therapy in sarcoidosis

- TNF-alpha blockade strategies have been studied because granuloma development is TNF-alpha dependent
  - Adalimumab
  - Infliximab

- Systematic review of 1525 patients shows (in some patients):
  - improvements in lung function in Pulmonary Sarcoid
  - Reduced target lesion area and Erythema in Cutaneous Sarcoid
  - Various Improvement s in Neurologic and Ocular Sarcoid
  - TNF blockade strategies had a steroid-sparing effect
  - TNF blockade strategies had comparable overall and serious adverse events to placebo, but slightly more infections

Adler BL et al, Semin Arthritis Rheum 2019 Jun, 48(6); 1093-1104

Evidence behind drug treatment in Sarcoidosis

3 Pharmacological treatment for pulmonary sarcoidosis

Intervention	Level of evidence*	Comment
Inhaled corticosteroids	A	Conflicting results from a small number of trials but essentially ineffective for control of pulmonary disease; may be effective for cough symptom control[43-45]
Oral corticosteroids	B	No robust placebo-controlled RCT; one non-randomised trial[46]
(Hydroxy) chloroquine	B	One small RCT in pulmonary disease; may be useful as a steroid-sparing agent[47]
Methotrexate	A	Steroid-sparing agent: one small RCT in pulmonary disease[48] and several case series in extra-pulmonary disease[49]
Azathioprine	B	Steroid sparing[50,51]
Mycophenolate	C	Steroid sparing[52,53]
Leflunomide	B	Steroid sparing[54,55]
Infliximab	A	Two RCTs demonstrating small effect in pulmonary disease; underpowered to demonstrate effect on extra-pulmonary manifestations[56,57]
Adalimumab	B	One small RCT in skin disease and case series pulmonary disease; lower rates of immunogenicity and allergy symptoms[58-60]

RCT = randomised controlled trial. * Level A: at least one double-blind, placebo-controlled trial with positive results with one or more case series supporting the results. Level B: majority of case series showing positive results. Level C: case series with mixed reports of effectiveness, or only a small number of cases reported. Levels of evidence as proposed by Guyatt G, Gutterman D, Baumann MH, et al. Grading strength of recommendations and quality of evidence in clinical guidelines: report from an American College of Chest Physicians task force. *Chest* 2006; 129: 174-181. ◆

Ahmadzai H et al, MJA 2018; 208(11); 499-504

Follow up in sarcoidosis

- Follow up whilst on treatment and for a period after remission to ensure no recurrence
- Advise such patients and GPs to be vigilant for recurrence

Follow up in sarcoidosis



Prognosis & Outcomes in sarcoidosis

- Spontaneous remission occurs in 2/3 of affected individuals
- Overall prognosis is good with more than 70% of patients eventually showing no evidence of disease activity (but may have residual pulmonary radiology change)
- Long-term active disease develops in a minority and management of sarcoid and sarcoid complications is more difficult

Ahmadzai H et al, MJA 2018; 208(11); 499-504

Prognosis & Outcomes in sarcoidosis

Favourable prognostic factor	Unfavourable prognostic factor
White race	Black race
Erythema Nodosum	Age > 40
Lofgren's syndrome	Organomegaly
	Lupus pernio
	Cardiac disease
	Nephrocalcinosis
	Sarcoid of the Upper Respiratory Tract
	Bone involvement
	Lower family income
	Extrapulmonary disease

Baughman RP & du Bois (Eds), Diffuse Lung Disease 2012, Springer (pubs)

Major complications in end-stage pulmonary disease

- Advanced pulmonary disease occurs in approx 5% of patients and account for most of the associated morbidity and mortality
- ***Pulmonary hypertension***
  - Usually seen in advanced pulmonary disease
  - Rarely occurs due to granulomatous infiltration of pulmonary vessels
  - or from nodal compression of pulmonary arteries
  - Or secondary to Left Ventricular dysfunction
  - RCT of Bosentan in sarcoid-associated pulmonary hypertension had no benefit

Spagnolo P et al, Lancet Respir Med 2018; 6; 389-402

Major complications in end-stage pulmonary disease

- ***Chronic pulmonary aspergillosis***
  - Mycetomas of Aspergillus may be present in 3-12% of cases of Advanced Pulmonary Sarcoidosis (stage IV).
  - Outcomes of sarcoid patients with mycetomas are worse than those of patients without them
  - Can be asymptomatic
  - May require antifungal therapy, surgical resection or bronchial artery embolisation for haemoptysis

Spagnolo P et al, Lancet Respir Med 2018; 6; 389-402

- ***Chronic pulmonary aspergillosis***



- ***Chronic pulmonary aspergillosis***



Major complications in end-stage pulmonary disease

- ***Acute exacerbations***
  - Acute exacerbations can occur in advanced pulmonary sarcoidosis due to:
    - Worsening of underlying sarcoidosis
    - Infection (particularly if bronchiectasis is present or the patient is immunosuppressed (exp TNF-alpha blockade)
    - Acute bronchospasm

Spagnolo P et al, Lancet Respir Med 2018; 6; 389-402

Indications for Transplant

- Transplant rarely undertaken in sarcoidosis
  - 31% of lung transplants occur for IPF vs only 2.6% for sarcoidosis
- Indicated for advanced fibrocystic disease with failed medical therapy
- NYHA 3 or 4
- Hypoxia at rest or Pulmonary Hypertension with P_{ra} ≥15mmHg
- Other multi-system sarcoid manifestations (e.g cardiac) must be non-severe and controlled
- Fibrocystic disease may make surgery difficult
- Mycetomas are a relative contra-indication

Shlobin et al, Eur Resp J 2012; 39; 1520-1533

Summary

- Sarcoidosis is a multi-system granulomatous disease of unknown cause
- Affects lungs in 95% of cases
- Diagnosis typically requires presence of noncaseating granuloma on histopathological examination, a compatible presentation and the exclusion of other causes of granulomatous inflammation
- Spontaneous remission occurs in 2/3 of affected individuals
- Treatment is not always necessary, but for severe or progressive disease corticosteroids, cytotoxics, or TNF-alpha blockade strategies are indicated
- Overall prognosis is good with more than 70% of patients eventually showing no evidence of disease activity (but may have residual pulmonary radiology change)